e-learning
resources
ERJ
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency
Hallstrand T.S., Ochs H.D., Zhu Q., Liles W.C.
Source:
Eur Respir J 2004; 24: 367-370
Journal Issue:
September
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hallstrand T.S., Ochs H.D., Zhu Q., Liles W.C.. Inhaled IFN-γ for persistent nontuberculous mycobacterial pulmonary disease due to functional IFN-γ deficiency. Eur Respir J 2004; 24: 367-370
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Re-activation of bovine tuberculosis in a patient treated with infliximab
Source: Eur Respir J 2008; 32: 229-231
Year: 2008
Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis
Source: Eur Respir J 2003; 21: 483-488
Year: 2003
Pulmonary infections in patients receiving treatment of tumor necrosis factor alpha antagonists
Source: International Congress 2015 – Immunodepression and severe pneumonia
Year: 2015
Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test?
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Interferon-γ therapy in two patients with progressive chronic pulmonary aspergillosis
Source: Eur Respir J 2006; 27: 1307-1310
Year: 2006
Isoniazid protection and risk of tuberculosis in patients who used anti tumor necrosis factor-alpha treatment
Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease
Year: 2007
Miliary tuberculosis during treatment with anti TNF alpha - a report of four cases
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II
Year: 2013
Mycolic acid from
mycobacterium tuberculosis
suppresses experimental asthma by triggering the local induction of regulatory T cells
Source: Annual Congress 2006 - Cellular immunology in asthma pathogenesis
Year: 2006
Interferon gamma (IFN?) pathway deficiency and severe NTM disease
Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Year: 2021
Variability of sputum inflammatory mediators in COPD and ?1-antitrypsin deficiency},
Source: Eur Respir J 2012; 40: 561-569
Year: 2012
Utility of mycobacterium tuberculosis Rv0081-specific host gene expression to distinguish latent infection from active tuberculosis disease
Source: International Congress 2016 – Active and latent tuberculosis: biomarkers
Year: 2016
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
Source: Eur Respir J 2010; 36: 1185-1206
Year: 2010
Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis
Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection
Year: 2006
Diagnosing latent tuberculosis in immunocompromised patients measuring blood IP-10 production capacity: An analysis of chronic renal faulire patients
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003
Clinical relevance of Mycobacterium simiae in pulmonary samples
Source: Eur Respir J 2008; 31: 106-109
Year: 2008
Is low body fat responsible for increased susceptibility to nontuberculous mycobacterial lung disease?
Source: Annual Congress 2013 –Interesting cases of respiratory infections
Year: 2013
Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis
Source: Eur Respir J 2003; 21: 421-428
Year: 2003
Could pulmonary tuberculosis present without any inflammatory response?
Source: Eur Respir J 2005; 26: Suppl. 49, 420s
Year: 2005
Silica exposure, silicosis, autoimmune diseases, tuberculosis and nontuberculous pulmonary mycobacterial disease
Source: International Congress 2016 – Occupational epidemiology
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept